Executive Team

Home>
About Us>
Executive Team

Executive Director and Global Chief Financial Officer

V. S. Mani

V.-S.-Mani

Mr. V.S. Mani is Executive Director and Global Chief Financial Officer at Glenmark Pharmaceuticals Limited. He is responsible for the company’s worldwide finance, secretarial and legal operations including global accounting, financial reporting, tax and treasury functions. He has about 30 years of industry experience across treasury, taxation (direct, indirect and international), accounting, financial planning and analysis, secretarial, legal, audits (internal and statutory), risk management and investor relations.

Prior to joining Glenmark in 2017, he was the President Finance at the Bhartiya Group. He has also held the position of the Chief Financial Officer at Cipla and played a key role in acquisition of various companies in emerging and mature markets for the organization. He is a Chartered Accountant by qualification.

President and Chief Executive Officer - Ichnos Glenmark Innovation

Cyril Konto

cyril

Dr. Cyril Konto is responsible for the overall management at Ichnos Glenmark Innovation. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Dr. Konto was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.

At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. Dr. Konto began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY^® (ipilimumab) melanoma program. An oncologist by training, Dr. Konto received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.

President and Business Head – India Formulations

Alok Malik

alok

Mr. Alok Malik is President and Business Head – India Formulations for Glenmark. He is responsible for driving the India Formulations business and growing it across the therapy areas of dermatology, respiratory, oncology, critical care, cardio-metabolic, and OTC (over-the-counter).

Mr. Malik brings over three decades of experience in managing the life cycle of pharmaceutical brands and has successfully launched over a hundred products across major therapy areas in the Indian Pharmaceutical Market. He has played a key role in ensuring seamless business transitions following mergers and brand acquisitions. Prior to joining Glenmark in 2018, Mr. Malik was Country Head for Abbott’s diagnostic business in India. He has also been associated with Piramal Healthcare in various roles for over a decade.

Mr. Malik is a science graduate and has completed his MBA from the University of Indore, specializing in Marketing.

President and Business Head – North America

Marc T. Kikuchi

marc_t

Mr. Marc T. Kikuchi is the President and Business Head of North America at Glenmark Pharmaceuticals Limited. He is responsible for the operations, strategic and growth portfolio of the company in the region. Spanning over three decades, Mr. Kikuchi has held multiple and diverse roles of increasing responsibility. Prior to joining Glenmark in 2024, he worked with Dr. Reddy’s Laboratories, Zydus Pharmaceuticals and Amerisourcebergen Corporation amongst other organizations in the pharmaceuticals industry.

Mr. Kikuchi is a graduate in Molecular and Cell Biology from University of California at Berkeley and a MBA from Carnegie Mellon University.

President and Business Head – Europe and Emerging Markets

Christoph Stoller

christoph

Mr. Christoph Stoller is the President and Business Head of Europe and Emerging Markets at Glenmark. He provides strategic leadership for bringing greater focus and alignment across Europe and the emerging markets (Asia, Russia/CIS, Middle East, Africa and Latin America), to better serve the needs of patients.

Mr. Stoller has over two and a half decades of experience in the industry, where he has successfully led and transformed businesses for growth across multiple geographies. Prior to joining Glenmark, Mr. Stoller was General Manager for Teva´s Germany and Austria cluster, he also served as Chief Operating Officer – Global Generic Medicines, Europe. He was President and Board Member of Medicines for Europe, an association for generics, biosimilar and value added medicines companies that is responsible for nearly 70% of the pharmaceutical supply in Europe. He has also had significant and successful stints with Zur Rose Group, Helvepharm, DSM, F. Hoffmann-La Roche, and Swiss Re.

Mr. Stoller is a Swiss citizen and has a degree in Business Administration from the University of St. Gallen, Switzerland (lic.oec.HSG).

President and Head - Global Pharmaceutical Development

Ulhas Dhuppad

ulhas_dhuppad

Mr. Ulhas Dhuppad is the President and Head of Global Pharmaceutical Development at Glenmark Pharmaceuticals Limited. He is responsible for driving generics research, specialty formulations, global regulatory affairs, and project management.

He brings with him rich experience spanning more than three decades. In this duration, he has developed more than 300 products including complex generics for USA and Europe and many specialty products for emerging markets. Mr. Dhuppad has been instrumental in designing development strategies and successfully filing niche products and has expertise in development of complex dosage forms. His areas of focus include setting of systems for robust and in time product development. Mr. Dhuppad has worked in some of the leading pharmaceutical companies like Cadila Laboratories, Cipla, Lupin, and Morepen Laboratories. He was previously associated with Glenmark for 15 years leading CMC development, and during this period he was a key contributor in building the Global Formulations R&D function. More recently, he was the President of Research & Development at Alkem Laboratories. Mr. Dhuppad holds a Master’s Degree in Pharmacy from Pune University.

President and Global Head – Formulation Operations

Brijlal Motwani

brijlal_motwani_new_1

Mr. Brijlal Motwani is the President and Global Head – Formulation Operations at Glenmark where he is responsible for demand and supply planning, procurement, project management and strategic change management initiatives at ten state-of-the-art manufacturing facilities across India, the USA, Argentina and the Czech Republic.

He has extensive experience of over three decades in Manufacturing and Operations, and has driven operations transformation programs, with leading pharmaceutical organizations in India as well as abroad. Mr. Motwani has been instrumental in improving productivity, debottlenecking operations, and developing long-term strategies for supply chains. He has successfully supported multiple organisations through numerous regulatory audits like those by the U.S. FDA, MHRA, EMEA, and ANVISA, among others.

Prior to joining Glenmark in 2019, he was Manufacturing Cluster Head at Zydus Lifesciences; leading several sites in India, the USA and Brazil. Mr. Motwani was Regional Manufacturing Head at Sun Pharma and led several manufacturing sites in Africa. He has also worked with Ranbaxy Laboratories, Dr. Reddy’s Laboratories, Cipla and Macleods Pharmaceuticals across multiple locations in India and overseas.

Mr. Motwani is a postgraduate in Pharmacy from Nagpur University.

President and Chief Quality Officer

Indrajit Bose

indra_bose

Mr. Indrajit Bose is the President and Chief Quality Officer at Glenmark. He heads the Quality function for Glenmark’s ten state-of-the-art manufacturing facilities across India, the USA, Argentina and the Czech Republic. He brings with him over thirty years of rich and varied experience in the pharmaceutical industry, across quality and manufacturing of formulations and active pharmaceutical ingredients (API). Mr. Bose has successfully guided various organizations through regulatory audits like the U.S. FDA, MHRA, and ANVISA.

Prior to joining Glenmark in 2022, Mr. Bose headed the global quality and compliance function for Dr. Reddy’s Laboratories. He has also held senior leadership roles across leading pharmaceutical companies like Lupin, Alembic, Medley, IPCA and ORGANON.

Mr. Bose is a Pharmacy graduate from Birla Institute of Management, Mesra, Ranchi and completed his P.G.D.M. from Brilliant School of Management, Chennai.

Executive Vice President and Head – Legal, Compliance and Intellectual Property

Samir Kazi

samir_kazi

Mr. Samir Kazi is the Executive Vice President and Head of Legal, Compliance and Intellectual Property at Glenmark Pharmaceuticals Limited. He is responsible for furthering the organization’s focus on maintaining high standards of ethics and business conduct.

Mr. Kazi has twenty four years of global experience in corporate consulting, corporate and statutory compliance, litigation, legal affairs, risk mitigation and management, mergers and acquisitions across diverse industries.

He has previously worked with Pfizer India, the Hinduja Group, Mulla & Mulla, and Craigie Blunt & Caroe. Mr Kazi is a Bachelor in Legislative Law from Mumbai University and a Bachelor of Commerce in Financial Accountancy and Taxation.

President and Chief Human Resources Officer

Alind Sharma

Mr. Alind Sharma is the President and Chief Human Resources Officer at Glenmark Pharmaceuticals Limited. He is responsible for driving organizational advancement through effective human capital strategy. His areas of focus comprise enriching and developing the organization’s diverse talent, appropriate and timely rewards through robust performance management, leadership development and talent engagement.

Mr. Sharma has re-joined Glenmark, having earlier been with the organization from the year 2002 to 2010. Prior to the current role with Glenmark, he was the Vice President of Human Capital at Optum, a part of the United Health Group. Mr. Sharma has also held senior positions with Pfizer, Monsanto, Tata International and Ranbaxy. He is a Post-Graduate from Indian Institute of Management, Ahmedabad, India.

ABOUT US

INNOVATION

PRODUCTS

RESPONSIBILITY

INVESTORS

INVESTORS

CAREERS

MEDIA

Executive Team

© 2024 GLENMARK PHARMACEUTICALS LTD. ALL RIGHTS RESERVED